Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B-cell maturation antigen CAR-T cell therapy - Pregen ShenZhen Biotechnology

Drug Profile

B-cell maturation antigen CAR-T cell therapy - Pregen ShenZhen Biotechnology

Alternative Names: BCMA CAR-T cell therapy - Pregene Shenzhen Biotechnology; BCMA nano-antibody CAR-T cell therapy - Pregene Shenzhen Biotechnology

Latest Information Update: 08 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pregene ShenZhen Biotechnology
  • Developer Henan Cancer Hospital; Pregene ShenZhen Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 31 May 2019 Interim adverse events and efficacy data from a phase I trial in multiple myeloma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 11 Apr 2018 Pregene ShenZhen Biotechnology initiates enrolment in a phase I trial for Multiple Myeloma (In adults, In the elderly, Second-line therapy or greater) in China (NCT03664661)
  • 10 Apr 2018 Pregene ShenZhen Biotechnology initiates enrolment in an early phase I trial for Multiple Myeloma (In adults, In the elderly, Second-line therapy or greater) in China (NCT03661554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top